AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Small nuclear ribonucleoprotein-associated proteins B and B'

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P14678

UPID:

RSMB_HUMAN

Alternative names:

Sm protein B/B'

Alternative UPACC:

P14678; Q15490; Q6IB35; Q9UIS5

Background:

Small nuclear ribonucleoprotein-associated proteins B and B', also known as Sm protein B/B', play a crucial role in pre-mRNA splicing. They are core components of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs), essential for the spliceosome's assembly and function. These proteins are involved in the splicing of U12-type introns and in histone pre-mRNA 3'-end processing, highlighting their importance in RNA metabolism.

Therapeutic significance:

The association of Small nuclear ribonucleoprotein-associated proteins B and B' with Cerebrocostomandibular syndrome, a condition marked by severe micrognathia, rib defects, and intellectual disability, underscores their potential as targets for therapeutic intervention. Understanding the role of these proteins could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.